BioScale Inc., a privately-held Cambridge life sciences company, said it has secured $25 million in its recent financing round.
BioScale said it is focused on a protein analytics technology that aims to accelerate drug discovery, development, and production of biological and pharmaceutical products.
"Led by new investor Morningside Venture, this round will be used to expand manufacturing operations and commercial sales of the ViBE protein analytics systems," BioScale said in a press release. "Also participating in the financing were existing investors New Science Ventures, WFD Ventures, F2 Ventures, and several individual investors."
According to BioScale, Morningside Venture is a diversified investment group that has been an active investor in China's emerging biotechnology sector.